Masakazu Sugino
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Masakazu Sugino has a total of 58 co-authors. Here are the top co-authors by number of shared publications:
- Toshiaki Hanafusa
Sakai City Medical Center, Sakai, Japan
3 shared publications Akane Ishida
Department of Respiratory Medicine National Center for Global Health and Medicine Tokyo Japan
2 shared publications- Hideto Nakajima
Division of Neurology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan
2 shared publications Nobuyuki Negoro
First Department of Internal Medicine
2 shared publications- Shinyu Izumi
Department of Respiratory Medicine, National Center for Global Health and Medicine, Tokyo, Japan
2 shared publications Ai Yoshida
Ibaraki, Japan, Otsu, Japan
1 shared publication
Latest Publications
- Open Access
- 6 May 2026
- Published by Wiley in Respirology Case Reports
- Vol. 14 (5)
Aspergillus Infection of a Postoperative Thoracic Cavity
A 72‐year‐old man developed Aspergillus infection within a postoperative thoracic cavity after lobectomy. Imaging showed cavity wall thickening with bronchopleural communication. Fenestration revealed characteristic purulent pleural debris and fungal masses. This case highlights Aspergillus pleurisy as a postoperative complication.
- 6 May 2026
- Published by Wiley in Respirology Case Reports
- Vol. 14 (5)
Open AccessAspergillus Infection of a Postoperative Thoracic Cavity
A 72‐year‐old man developed Aspergillus infection within a postoperative thoracic cavity after lobectomy. Imaging showed cavity wall thickening with bronchopleural communication. Fenestration revealed characteristic purulent pleural debris and fungal masses. This case highlights Aspergillus pleurisy as a postoperative complication.
- Open Access
- 30 July 2025
- Published by Wiley in Respirology Case Reports
- Vol. 13 (8) , e70302
Intractable Pyopneumothorax due to Lemierre's Syndrome Treated With an Endobronchial Watanabe Spigot (EWS)
Lemierre's syndrome is a rare condition characterised by internal jugular vein thrombophlebitis and bacteremia caused by anaerobic organisms following an oropharyngeal infection. We report the case of a 29‐year‐old woman who presented with fever, sore throat, dyspnea, and chest pain. Chest computed tomography (CT) revealed lung suppuration, pneumothorax, and thrombosis of the left internal jugular vein, confirming the diagnosis of Lemierre's syndrome. During treatment, she developed pyothorax with bronchopleural fistulas and intractable pneumothorax. Although antibiotics and thoracic drainage controlled the infection, persistent air leakage and incomplete lung expansion remained. Placement of an endobronchial watanabe spigot (EWS) successfully resolved the air leak, allowing the patient to avoid surgery and be discharged. This case highlights the effectiveness of EWS in managing intractable pyopneumothorax secondary to Lemierre's syndrome.
- 30 July 2025
- Published by Wiley in Respirology Case Reports
- Vol. 13 (8) , e70302
Open AccessIntractable Pyopneumothorax due to Lemierre's Syndrome Treated With an Endobronchial Watanabe Spigot (EWS)
Lemierre's syndrome is a rare condition characterised by internal jugular vein thrombophlebitis and bacteremia caused by anaerobic organisms following an oropharyngeal infection. We report the case of a 29‐year‐old woman who presented with fever, sore throat, dyspnea, and chest pain. Chest computed tomography (CT) revealed lung suppuration, pneumothorax, and thrombosis of the left internal jugular vein, confirming the diagnosis of Lemierre's syndrome. During treatment, she developed pyothorax with bronchopleural fistulas and intractable pneumothorax. Although antibiotics and thoracic drainage controlled the infection, persistent air leakage and incomplete lung expansion remained. Placement of an endobronchial watanabe spigot (EWS) successfully resolved the air leak, allowing the patient to avoid surgery and be discharged. This case highlights the effectiveness of EWS in managing intractable pyopneumothorax secondary to Lemierre's syndrome.
- 9 November 2024
- Published by Elsevier in Respiratory Investigation
- Vol. 62 (6) , 1227-1232
Preliminary investigation of the significance of cavitary lesions in recurrent hemoptysis following bronchial artery embolization for nontuberculous mycobacterial pulmonary disease
- 9 November 2024
- Published by Elsevier in Respiratory Investigation
- Vol. 62 (6) , 1227-1232
Preliminary investigation of the significance of cavitary lesions in recurrent hemoptysis following bronchial artery embolization for nontuberculous mycobacterial pulmonary disease
- 1 June 2021
- Published by American Diabetes Association in Diabetes
- Vol. 70 (Supplement)
671-P: Liraglutide Possibly Prevents Progression of Dementia in Patients with Type 2 Diabetes
Purpose: The purpose of this study is to assess the usefulness of liraglutide in elderly patients with type 2 diabetes to prevent progression of dementia. Methods: We retrospectively reviewed 31 outpatients with 65 years of age or older, who have been treated with liraglutide for 6 years (Group G; 12 males/19 females, 73.1 ± 8.6 years-old, HbA1c 7.5 ± 0.4%, 9 patients with cerebrovascular diseases, 8 patients with cardiovascular diseases, 16 patients with insulin therapy). Daily dose of liraglutide was 0.9 mg except 2 patients (0.6 mg). We examined Voxel-based Specific Regional Analysis System for Alzheimer’s Disease (VSRAD) on MRI, max-IMT measured by carotid artery ultrasonography, visceral fat area, concentrations of HbA1c and FPG, serum levels of CRP, HDL/LDL cholesterol, and TG, both before and after the treatment. Age, HbA1c, and VSRAD values-matched 16 patients who were treated with linagliptin were analyzed as a control (Group D). Results: After 6 years, VSRAD was significantly deteriorated in Group D (1.06±0.98→1.39±1.05 (p2 (NS)). CRP was decreased in Group G (0.12±0.11→0.09±0.12mg/dl (p<0.01)). HbA1c (7.5±0.4 → 7.0±0.5 vs. 7.3±0.3 → 6.8±0.4%), FPG (137±19 → 121±11 vs. 129±12→110±15mg/dl), were significantly improved in both groups (p<0.01). No hypoglycemia requiring medical intervention was observed. Only TG in Group G (167±53→147±34mg/dl (p <0.01)) was improved in lipid parameters. During the 6 years, antidementia drugs were prescribed for 2 patients in both groups. A stroke event was found in a patient of Group D. Conclusion: Liraglutide possibly prevent progression of dementia. The reduction of visceral obesity may contribute to this beneficial effect through anti-arteriosclerosis. Disclosure M. Yoshida: None. A. Yoshida: None. E. Oh: None. N. Yamamoto: None. E. Sasaki: None. S. Yoshida: None. N. Ohsawa: None. M. Sugino: None. I. Koyama: None.
- 1 June 2021
- Published by American Diabetes Association in Diabetes
- Vol. 70 (Supplement)
671-P: Liraglutide Possibly Prevents Progression of Dementia in Patients with Type 2 Diabetes
Purpose: The purpose of this study is to assess the usefulness of liraglutide in elderly patients with type 2 diabetes to prevent progression of dementia. Methods: We retrospectively reviewed 31 outpatients with 65 years of age or older, who have been treated with liraglutide for 6 years (Group G; 12 males/19 females, 73.1 ± 8.6 years-old, HbA1c 7.5 ± 0.4%, 9 patients with cerebrovascular diseases, 8 patients with cardiovascular diseases, 16 patients with insulin therapy). Daily dose of liraglutide was 0.9 mg except 2 patients (0.6 mg). We examined Voxel-based Specific Regional Analysis System for Alzheimer’s Disease (VSRAD) on MRI, max-IMT measured by carotid artery ultrasonography, visceral fat area, concentrations of HbA1c and FPG, serum levels of CRP, HDL/LDL cholesterol, and TG, both before and after the treatment. Age, HbA1c, and VSRAD values-matched 16 patients who were treated with linagliptin were analyzed as a control (Group D). Results: After 6 years, VSRAD was significantly deteriorated in Group D (1.06±0.98→1.39±1.05 (p2 (NS)). CRP was decreased in Group G (0.12±0.11→0.09±0.12mg/dl (p<0.01)). HbA1c (7.5±0.4 → 7.0±0.5 vs. 7.3±0.3 → 6.8±0.4%), FPG (137±19 → 121±11 vs. 129±12→110±15mg/dl), were significantly improved in both groups (p<0.01). No hypoglycemia requiring medical intervention was observed. Only TG in Group G (167±53→147±34mg/dl (p <0.01)) was improved in lipid parameters. During the 6 years, antidementia drugs were prescribed for 2 patients in both groups. A stroke event was found in a patient of Group D. Conclusion: Liraglutide possibly prevent progression of dementia. The reduction of visceral obesity may contribute to this beneficial effect through anti-arteriosclerosis. Disclosure M. Yoshida: None. A. Yoshida: None. E. Oh: None. N. Yamamoto: None. E. Sasaki: None. S. Yoshida: None. N. Ohsawa: None. M. Sugino: None. I. Koyama: None.
- 13 October 2006
- Published by Wiley in European Journal of Neurology
- Vol. 13 (11) , e4-e6
Epstein–Barr virus‐associated primary leptomeningeal lymphoma
- 13 October 2006
- Published by Wiley in European Journal of Neurology
- Vol. 13 (11) , e4-e6
Epstein–Barr virus‐associated primary leptomeningeal lymphoma
- Open Access
- 1 January 2005
- Published by Japanese Society of Internal Medicine in Internal Medicine
- Vol. 44 (2) , 129-135
Re-entry Circuit in Ventricular Tachycardia Due to Focal Fatty-fibrosis in a Patient with Myotonic Dystrophy
A 69-year-old man with a recurrent ventricular tachycardia (VT) was admitted. The patient was diagnosed as myotonic dystrophy type 1 (DM1) and DNA analysis revealed 1,800 CTG-repeat expansion in the myotonic dystrophy protein kinase (DMPK) gene. Ultrasonic cardiogram (UCG), left ventriculogram (LVG) and magnetic resonance imaging (MRI) did not show any abnormal sign including fatty infiltration. But, endomyocardial biopsy obtained from ventricular outflow tract revealed severe fatty infiltration and interstitial fibrosis. Radiofrequency catheter ablation at the biopsy site could eliminate VT, so it was strongly suggested that the re-entry circuit was formed by focal fatty-fibrosis. Careful observation should be continued for a long period.
- 1 January 2005
- Published by Japanese Society of Internal Medicine in Internal Medicine
- Vol. 44 (2) , 129-135
Open AccessRe-entry Circuit in Ventricular Tachycardia Due to Focal Fatty-fibrosis in a Patient with Myotonic Dystrophy
A 69-year-old man with a recurrent ventricular tachycardia (VT) was admitted. The patient was diagnosed as myotonic dystrophy type 1 (DM1) and DNA analysis revealed 1,800 CTG-repeat expansion in the myotonic dystrophy protein kinase (DMPK) gene. Ultrasonic cardiogram (UCG), left ventriculogram (LVG) and magnetic resonance imaging (MRI) did not show any abnormal sign including fatty infiltration. But, endomyocardial biopsy obtained from ventricular outflow tract revealed severe fatty infiltration and interstitial fibrosis. Radiofrequency catheter ablation at the biopsy site could eliminate VT, so it was strongly suggested that the re-entry circuit was formed by focal fatty-fibrosis. Careful observation should be continued for a long period.
- 7 May 2004
- Published by Elsevier in Neuroscience Letters
- Vol. 363 (2) , 187-189
Decreased CD14+CCR2+ monocytes in active multiple sclerosis
- 7 May 2004
- Published by Elsevier in Neuroscience Letters
- Vol. 363 (2) , 187-189
Decreased CD14+CCR2+ monocytes in active multiple sclerosis
- Open Access
- 1 January 1996
- Published by Japanese Circulation Society in Japanese Circulation Journal
- Vol. 60 (8) , 618-623
Coronary Artery to Pulmonary Artery Fistula With TWO Giant Saccular Aneurysms in an Elderly Patient Determined Noninvasively
An 87-year-old woman was admitted to our hospital on an emergency basis with atypical chest pain and dyspnea. She had a continuous precordial murmur. Electrocardiogram showed no evidence of myocardial ischemia, but chest X-ray showed marked enlargement of the cardiac silhouette and an abnormal calcified vascular structure. Computed tomography of the chest revealed large abnormal masses next to the heart. Two-dimensional echocardiography showed enlargement of the main trunk of the left coronary artery and 2 giant saccular aneurysms. Abnormal diastolic inflow to the main pulmonary trunk was also observed by color flow imaging. These findings were supported by data obtained using magnetic resonance imaging and transesophageal echocardiography. Based on the above findings, we diagnosed this case as a coronary artery fistula originating from the proximal left anterior descending artery associated with 2 giant saccular aneurysms draining into the pulmonary artery. To our knowledge, this is the oldest patient ever reported with such an anomaly. This case emphasizes that a good prognosis is possible even with a very pronounced visible structural abnormality.
- 1 January 1996
- Published by Japanese Circulation Society in Japanese Circulation Journal
- Vol. 60 (8) , 618-623
Open AccessCoronary Artery to Pulmonary Artery Fistula With TWO Giant Saccular Aneurysms in an Elderly Patient Determined Noninvasively
An 87-year-old woman was admitted to our hospital on an emergency basis with atypical chest pain and dyspnea. She had a continuous precordial murmur. Electrocardiogram showed no evidence of myocardial ischemia, but chest X-ray showed marked enlargement of the cardiac silhouette and an abnormal calcified vascular structure. Computed tomography of the chest revealed large abnormal masses next to the heart. Two-dimensional echocardiography showed enlargement of the main trunk of the left coronary artery and 2 giant saccular aneurysms. Abnormal diastolic inflow to the main pulmonary trunk was also observed by color flow imaging. These findings were supported by data obtained using magnetic resonance imaging and transesophageal echocardiography. Based on the above findings, we diagnosed this case as a coronary artery fistula originating from the proximal left anterior descending artery associated with 2 giant saccular aneurysms draining into the pulmonary artery. To our knowledge, this is the oldest patient ever reported with such an anomaly. This case emphasizes that a good prognosis is possible even with a very pronounced visible structural abnormality.